179 completed. 179 Phase 2, 40 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 179 | Completed 179 |
| Phase 1 | 40 | Completed 40 |
| Phase 3 | 6 | Completed 6 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta SION-719, Placebo-to-match SION-719 - Cystic Fibrosis (CF) | Phase 2 | Completed | Sionna Therapeutics Inc. | 15 | 2025-11-03 | 2026-09-10 |
| A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis ETD001, Placebo - Cystic Fibrosis | Phase 2 | Completed | Enterprise Therapeutics Ltd | 57 | 2024-06-26 | 2025-11-28 |
| A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis CMTX-101, Placebo - Persistent Infection, Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Clarametyx Biosciences, Inc. | 43 | 2024-06-24 | 2026-10-30 |
| Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF Diponecaftor, Placebo - Cystic Fibrosis | Phase 2 | Completed | Kors van der Ent | 41 | 2024-06-03 | 2025-11-24 |
| A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) BI 1291583, Placebo to BI 1291583 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Completed | Boehringer Ingelheim | 22 | 2024-04-05 | 2026-06-23 |
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection RSP-1502, Tobramycin inhalation solution - Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic | Phase 1 / Phase 2 | Completed | Respirion Pharmaceuticals Pty Ltd | 71 | 2024-04-01 | 2026-06-25 |
| Semaglutide in CFRD Semaglutide - Cystic Fibrosis, Cystic Fibrosis-related Diabetes | Phase 2 / Phase 3 | Completed | University of Minnesota | 8 | 2023-10-16 | 2026-01-21 |
| A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) VX-522 mRNA therapy, IVA - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 26 | 2023-02-27 | 2026-10-09 |
| Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis adrulipase - Exocrine Pancreatic Insufficiency, Cystic Fibrosis | Phase 2 | Completed | Entero Therapeutics | 13 | 2023-02-01 | 2024-09-19 |
| A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa Placebo, WRAIR-PAM-CF1 - Bacterial Disease Carrier, Cystic Fibrosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 73 | 2022-10-03 | 2026-07-16 |
| Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection BX004-A, Placebo - Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis | Phase 1 / Phase 2 | Completed | BiomX, Inc. | 43 | 2022-06-21 | 2025-07-18 |
| Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis Xenon MRI - Cystic Fibrosis | Phase 2 | Completed | University of Kansas Medical Center | 21 | 2022-03-15 | 2025-06-12 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis Brensocatib, Placebo - Cystic Fibrosis | Phase 2 | Completed | Insmed Incorporated | 29 | 2021-11-30 | 2026-03-12 |
| Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections BCG TICE Vaccine - Cystic Fibrosis, Bronchiectasis Adult | Phase 2 | Completed | Johns Hopkins University | 30 | 2021-04-28 | 2025-02-10 |
| CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) Standard Dose YPT-01, Placebo - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Yale University | 8 | 2021-03-29 | 2023-11-18 |
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis AP-PA02, Placebo - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 29 | 2020-12-22 | 2024-01-31 |
| OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis MS1819, Porcine PERT - Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Completed | Entero Therapeutics | 27 | 2020-07-20 | 2022-09-13 |
| A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 ABBV-3067, Placebo ABBV-3067, ABBV-2222 - Cystic Fibrosis | Phase 2 | Completed | AbbVie | 78 | 2019-12-11 | 2023-06-28 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele ELX-02, Ivacaftor - Cystic Fibrosis | Phase 2 | Completed | Eloxx Pharmaceuticals, Inc. | 17 | 2019-11-25 | 2022-11-22 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele ELX-02, Ivacaftor - Cystic Fibrosis | Phase 2 | Completed | Eloxx Pharmaceuticals, Inc. | 17 | 2019-11-05 | 2023-08-21 |
Showing 20 of 179. Sign in to see all of them.
Pseudomonas Infections (15) · Exocrine Pancreatic Insufficiency (10) · Lung Diseases (9) · Genetic Diseases, Inborn (5) · Respiratory Tract Diseases (5) · Inflammation (4) · Respiratory Tract Infections (4) · Digestive System Diseases (3) · Infections (3) · Pancreatic Diseases (3) · Asthma (2) · Bacterial Infections (2) · Bronchiectasis (2) · Infant, Newborn, Diseases (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (179) · Infant, Newborn, Diseases (177) · Digestive System Diseases (176) · Pancreatic Diseases (176) · Genetic Diseases, Inborn (174) · Respiratory Tract Diseases (174) · Lung Diseases (170) · Infections (24) · Bacterial Infections and Mycoses (20) · Bacterial Infections (17) · Gram-Negative Bacterial Infections (16) · Pathological Conditions, Signs and Symptoms (16) · Pathologic Processes (13) · Bronchial Diseases (6) · Disease Attributes (6)
ivacaftor (21) · tezacaftor (9) · Saline Solution, Hypertonic (8) · tezacaftor, ivacaftor drug combination (8) · Inhalation (7) · Sodium Chloride (7) · Saline Solution (5) · Sildenafil Citrate (5) · ataluren (4) · denufosol tetrasodium (4) · GLPG2222 (3) · Mannitol (3) · Nitric Oxide (3) · Tobramycin (3) · dornase alfa (3)
Vertex Pharmaceuticals Incorporated (20) · Lakefront Biotherapeutics NV (5) · Merck Sharp & Dohme LLC (5) · National Jewish Health (5) · Insmed Incorporated (4) · PTC Therapeutics (4) · Syntara (4) · The Hospital for Sick Children (4) · AlgiPharma AS (3) · Entero Therapeutics (3) · Gilead Sciences (3) · Johns Hopkins University (3) · Parion Sciences (3) · Proteostasis Therapeutics, Inc. (3) · Augusta University (2)
United States (106) · United Kingdom (39) · Germany (37) · Belgium (25) · Canada (24) · France (20) · Australia (18) · Netherlands (18) · Italy (13) · Israel (10) · Poland (10) · Spain (9) · Denmark (7) · Sweden (7) · Czechia (6)
Amy Schaberg, BSN (4) · Felix Ratjen, MD (3) · Gina Eagle, MD (3) · Jennifer L Taylor-Cousar, MD (3) · Stuart Elborn, MD (3) · Eitan Kerem, MD (2) · George Retsch-Bogart, MD (2) · James Chmiel, MD (2) · Jochen Mainz, M.D. (2) · Larry Lands, MD (2) · Olivier Van Steen, MD, MBA (2) · Olivier Van de Steen, MD, MBA (2) · Scott Donaldson, MD (2)
PMID 33331662, PMID 37983082, PMID 32671834, PMID 31215818, PMID 31056441, PMID 33735508, PMID 36511181, PMID 36842446, PMID 37319354, PMID 10459902, PMID 15704203, PMID 17050563, PMID 17337677, PMID 17446337, PMID 18339790, PMID 18722008, PMID 18972410, PMID 19635928, PMID 19643946, PMID 19880909, PMID 19996349, PMID 20622033, PMID 20630539, PMID 20961818, PMID 21083385, PMID 21195036, PMID 21233271, PMID 21471106, PMID 21825083, PMID 21893650, PMID 21896198, PMID 22267768, PMID 22995323, PMID 23333044, PMID 23407019, PMID 23412700, PMID 23588193, PMID 23631796, PMID 23749840, PMID 24019259, PMID 24345827, PMID 24461666, PMID 24518280, PMID 24528942, PMID 24571729, PMID 24596456, PMID 24660233, PMID 24973281, PMID 25091537, PMID 25188297
2015 (4), 2008 (3), 2016 (3), 2017 (3), 2014 (2), 2018 (2), 2019 (1), 2023 (1), 2UM1AI104681-08 (1), M01RR000037 (1), P01HL158507 (1), R01DK057755 (1), R01HL139876 (1), R21DK100783 (1), R44DK060302 (1)